论文部分内容阅读
作者通过动物实验和临床应用对肝脏疾患经静脉给予核苷和核苷酸的混合液 OG-Ⅵ进行了研究。OG-Ⅵ的组成和给药后的体内分布 OG-Ⅵ是参考肝脏核酸碱基的比率,从药理作用、组织摄取形式、安全性、制剂稳定性等方面进行了改造的输液剂。所含肌苷、胞嘧啶核苷,5′-磷酸鸟苷、尿嘧啶核苷、胸腺嘧啶核苷的克分子量比率是4∶4∶4∶3∶1。实验把标记的 OG-Ⅵ液注入大鼠体内,几小时
The authors investigated the OG-Ⅵ, a mixture of nucleosides and nucleotides intravenously administered to liver diseases through animal experiments and clinical applications. Composition of OG-VI and in vivo distribution after administration OG-VI is an infusion solution that has been modified from the aspects of pharmacological action, tissue uptake form, safety, formulation stability and the like with reference to the ratio of liver nucleic acid bases. The molecular weight ratio of inosine, cytidine, 5’-guanosine, uridine, and thymidine contained is 4: 4: 4: 3: 1. The labeled OG-Ⅵ fluid was injected into rats for several hours